πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

82 results for β€œinsulin” Clear

  1. albiglutide + insulin glargine

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 mab completed

    1 trial

  2. biphasic insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  3. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, METFORMIN , INSULIN DEGLUDEC , INSULIN (HUMAN) , INSULIN GLARGINE , cagrilintide semaglutide, INSULIN DETEMIR , Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  4. insulin degludec

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials

  5. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extensionβ€”assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic Ξ²-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  6. A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged β‰₯2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

    Alphapharm Pty Ltd

    Congenital Hyperinsulinism (CHI)

    phase 2 other active

    1 trial

  7. Glucagon

    Xeris Biopharma Holdings

    Congenital Hyperinsulinism

    phase 2 small molecule completed

    1 trial

  8. Glucagon RTU

    Xeris Biopharma Holdings

    Hyperinsulinemic Hypoglycemia

    phase 2 small molecule completed

    1 trial

  9. Glucagon RTU Injection With Insulin Pump Reduction

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  10. Insulin

    United Therapeutics Europe Ltd

    Multiple Sclerosis, Relapsing-Remitting

    phase 2 small molecule completed

    1 trial

  11. Insulin

    United Therapeutics Europe Ltd

    Acute Stroke

    phase 2 small molecule completed

    1 trial

  12. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type II

    phase 2 small molecule completed

    1 trial

  13. Insulin lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  14. ORMD-0801 (Insulin) capsule 8 mg BD

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  15. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial

  16. Oshadi Icp

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus, Insulin-Dependent, 1

    phase 2 small molecule completed

    1 trial

  17. Pro insulin peptide

    Cardiff Oncology

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  18. 68Ga-NOTA-MAL-Cys39-exendin-4

    The First People's Hospital of Lianyungang

    Insulinoma

    phase 1 small molecule active

    1 trial

  19. A Phase I Randomized, Single-center, Double-blind, Two-period Crossover Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Icodec in Participants with Type 2 Diabetes.

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  20. A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2DM) and overweight or obesity

    phase 1 other active

    1 trial

  21. A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

    Eli Lilly Co.

    Diabetes Mellitus

    phase 1 other active

    1 trial

  22. A Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Degludec and Insulin Icodec in Participants with Type 2 Diabetes

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  23. A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at steady state in participants with Type 1 Diabetes

    Lacuna Pharma Pty Ltd

    Type 1 diabetes Mellitus

    phase 1 other active

    1 trial

  24. A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources